Sarepta Therapeutics (SRPT) Position Has Increased by Natixis; Marvell Techology Group LTD (MRVL) Shareholder Broadview Advisors Has Boosted Its Position by $2.66 Million as Share Value Rose

Marvell Technology Group Ltd. (NASDAQ:MRVL) Logo

Broadview Advisors Llc increased its stake in Marvell Techology Group Ltd (MRVL) by 41.46% based on its latest 2018Q4 regulatory filing with the SEC. Broadview Advisors Llc bought 166,350 shares as the company’s stock rose 25.09% with the market. The institutional investor held 567,600 shares of the semiconductors company at the end of 2018Q4, valued at $9.19M, up from 401,250 at the end of the previous reported quarter. Broadview Advisors Llc who had been investing in Marvell Techology Group Ltd for a number of months, seems to be bullish on the $13.24 billion market cap company. The stock increased 3.76% or $0.73 during the last trading session, reaching $20.14. About 15.76M shares traded or 33.59% up from the average. Marvell Technology Group Ltd. (NASDAQ:MRVL) has declined 13.60% since March 17, 2018 and is downtrending. It has underperformed by 17.97% the S&P500. Some Historical MRVL News: 20/03/2018 – Marvell Introduces Industry’s First NVMe Chipset Solutions to Address Emerging Data Center SSD Requirements; 18/05/2018 – Kalray hires Allegra Finance to advise on Euronext IPO – CEO; 04/05/2018 – Netscout could attract activist looking for M&A deal –; 15/05/2018 – Standard Life Aberdeen Buys New 2.5% Position in Marvell Tech; 14/05/2018 – Marvell Tech Closes Above 50-Day Moving Average: Technicals; 08/03/2018 Mellanox adds Credit Suisse to enhance defense against Starboard; 27/03/2018 – Marvell Announces Integration of Industry’s First Secure Automotive Ethernet Switch into NVIDIA DRIVE Pegasus Platform for Level 5 Autonomy; 09/03/2018 – MARVELL TECHNOLOGY GROUP LTD MRVL.O : MORGAN STANLEY RAISES TARGET PRICE TO $23 FROM $22; 24/05/2018 – MARVELL SEES CAVIUM MERGER CLOSING MID-CALENDAR YEAR; 25/05/2018 – San Jose Bus Jrn: Exclusive: Here’s the privacy-protecting cloud storage idea Marvell’s co-founder is about to unveil

Natixis increased its stake in Sarepta Therapeutics Inc (SRPT) by 193.74% based on its latest 2018Q4 regulatory filing with the SEC. Natixis bought 26,254 shares as the company’s stock rose 13.40% with the market. The institutional investor held 39,805 shares of the health care company at the end of 2018Q4, valued at $4.34 million, up from 13,551 at the end of the previous reported quarter. Natixis who had been investing in Sarepta Therapeutics Inc for a number of months, seems to be bullish on the $9.46B market cap company. The stock decreased 0.81% or $1.05 during the last trading session, reaching $128.36. About 1.16M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 134.23% since March 17, 2018 and is uptrending. It has outperformed by 129.86% the S&P500. Some Historical SRPT News: 03/05/2018 – SAREPTA – WILL MAKE UPFRONT PAYMENT OF $60 MLN, ADDITIONAL MILESTONE PAYMENTS TO PURCHASE AN EXCLUSIVE OPTION TO ACQUIRE MYONEXUS; 09/04/2018 – STAT Plus: Pharmalittle: Novartis pays $9 billion for gene therapy company; Merck’s Keytruda scores a win; 17/05/2018 – Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination T; 10/04/2018 – Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International; 12/03/2018 – Sarepta Therapeutics Intends to Complete a Rolling NDA Submission for Golodirsen by Yr-end 2018; 24/04/2018 – MERCK PHASE 1 KEYTRUDA STUDY SUSPENDED: CLINICALTRIALS.GOV; 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 15/04/2018 – Merck: Keytruda First Anti-PD-1 Therapy to Show Recurrence-Free Survival Benefit Across Stage IIIA, IIIB, IIIC Melanoma; 04/05/2018 – SAREPTA THERAPEUTICS INC SRPT.O : NOMURA RAISES TARGET PRICE TO $131 FROM $96

Broadview Advisors Llc, which manages about $1.12B and $347.25M US Long portfolio, decreased its stake in Imperva Inc (NYSE:IMPV) by 285,225 shares to 5,500 shares, valued at $306,000 in 2018Q4, according to the filing. It also reduced its holding in Crane Co (NYSE:CR) by 39,725 shares in the quarter, leaving it with 88,000 shares, and cut its stake in Bok Finl Corp (NASDAQ:BOKF).

More notable recent Marvell Technology Group Ltd. (NASDAQ:MRVL) news were published by: Seekingalpha.com which released: “Marvell: Growth Outlook Improved With The Cavium Acquisition – Seeking Alpha” on September 18, 2018, also Globenewswire.com with their article: “Consolidated Research: 2019 Summary Expectations for Activision Blizzard, Marvell Technology Group, The Sherwin-Williams, T. Rowe Price Group, Employers, and Blue Bird — Fundamental Analysis, Key Performance Indications – GlobeNewswire” published on February 27, 2019, Nasdaq.com published: “Marvell Technology (MRVL) Q1 Earnings: What’s in the Cards? – Nasdaq” on May 29, 2018. More interesting news about Marvell Technology Group Ltd. (NASDAQ:MRVL) were released by: Fool.com and their article: “Better Buy: Cypress Semiconductor vs. Marvell – The Motley Fool” published on January 27, 2019 as well as Nasdaq.com‘s news article titled: “Marvell (MRVL) Down 4.4% Since Last Earnings Report: Can It Rebound? – Nasdaq” with publication date: October 06, 2018.

Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.53, from 1.46 in 2018Q3. It is negative, as 39 investors sold MRVL shares while 114 reduced holdings. 46 funds opened positions while 97 raised stakes. 610.28 million shares or 1.18% more from 603.15 million shares in 2018Q3 were reported. Montag & Caldwell Limited Liability Company holds 19,413 shares or 0.02% of its portfolio. Northwestern Mutual Wealth Management Co owns 6,326 shares. 438,617 were accumulated by Citigroup Inc. Shaker Invests Lc Oh stated it has 0.2% of its portfolio in Marvell Technology Group Ltd. (NASDAQ:MRVL). Fisher Asset Mngmt Lc has invested 0.04% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Bnp Paribas Arbitrage stated it has 0% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Parkside Comml Bank Trust has invested 0% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Bank & Trust Of Montreal Can stated it has 116,082 shares or 0% of all its holdings. Teton Advisors Incorporated accumulated 44,360 shares or 0.08% of the stock. Zweig reported 272,182 shares stake. Baker Avenue Asset Mngmt LP invested in 0.1% or 62,358 shares. Dnb Asset As owns 57,785 shares. Swedbank has invested 0.37% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Pub Employees Retirement Association Of Colorado holds 0.01% or 104,166 shares in its portfolio. Assetmark reported 242 shares or 0% of all its holdings.

Since October 24, 2018, it had 1 buy, and 7 sales for $38.17 million activity. $2.01M worth of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares were bought by INGRAM DOUGLAS S. 6,667 shares were sold by Wigzell Hans Lennart Rudolf, worth $936,714. 30,000 shares were sold by Howton David T, worth $4.20M. 65,000 shares valued at $9.43 million were sold by Mahatme Sandesh on Thursday, February 7. Another trade for 10,000 shares valued at $1.32M was made by BEHRENS M KATHLEEN on Wednesday, October 31.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “April 18th Options Now Available For Sarepta Therapeutics (SRPT) – Nasdaq” on January 14, 2019, also Benzinga.com with their article: “30 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” published on March 06, 2019, Benzinga.com published: “Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics (NASDAQ:ONCE) Deal – Benzinga” on February 25, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT – Nasdaq” published on March 06, 2019 as well as Nasdaq.com‘s news article titled: “Sum Up The Pieces: EQAL Could Be Worth $36 – Nasdaq” with publication date: March 04, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart